PSIL AdvisorShares Psychedelics ETF
ETF on NYSE (US) · Actively managed · Listing
Changes appear once four weeks of holdings are on file.
Largest holding: Definium Therapeutics, Inc., 153,124 shares ($4.50M).
| Current positions Top 10 | % of book |
|---|---|
| Definium Therapeutics, Inc. DFTX $4.50M | 11.8% |
| COMPASS Pathways Plc CMPS $3.95M | 10.4% |
| Helus Pharma Inc. HELP $2.82M | 7.4% |
| Eli Lilly and Company LLY $2.63M | 6.9% |
| Neurocrine Biosciences, Inc. NBIX $2.48M | 6.5% |
| AbbVie Inc. ABBV $2.36M | 6.2% |
| Indivior Pharmaceuticals, Inc. INDV $2.07M | 5.4% |
| Relmada Therapeutics, Inc. RLMD $2.00M | 5.2% |
| Seaport Therapeutics, Inc. SPTX $1.99M | 5.2% |
| Johnson & Johnson JNJ $1.91M | 5.0% |
Slices are % of holdings value.
| Sectors | % of long value |
|---|---|
| Healthcare | 98.7% |
| Unclassified | 1.3% |
| Industries | % of long value |
|---|---|
| Biotechnology | 70.0% |
| Drug Manufacturers - General | 18.1% |
| Drug Manufacturers - Specialty & Generic | 6.9% |
| Medical Devices | 3.7% |
| Unclassified | 1.3% |
Source: the fund's own published holdings, the portfolio of Nov 17, 2026 (advisorshares.com). Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Oct 30, 2026.
The AdvisorShares Psychedelics ETF (the "Fund") seeks long-term capital appreciation.
Principal investment strategies
The Fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by primarily investing in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid-, small- and micro-capitalization companies. The Fund also may invest in total return swaps intended to provide exposure to such companies. Under normal circumstances, Fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. Psychedelic drugs, also known as hallucinogens, are a group of substances, including psilocybin, that are used to change and enhance sensory perceptions, thought processes, and energy levels. Psychedelic medicines, therapeutics, and healthcare treatments may be used in the treatment of illnesses such as depression, addiction, anxiety and post-traumatic stress disorder. Psychedelic medicine companies include life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry, including producers or distributors of psychedelic medicines, biotechnology companies engaged in research and development of psychedelic medicines, and companies that provide psychotherapy treatments and mental health services using psychedelics. The Fund does not consider cannabis to be a psychedelic drug. The Fund will not invest directly in or hold ownership in any companies that engage in psychedelics-related business unless permitted by national and local laws of the relevant jurisdiction including, but not limited to, U.S. federal and state laws. The Fund concentrates (i.e., invests more than 25% of its total assets) in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The Fund is non-diversified and may invest a greater percentage of its assets in a particular issuer than a diversified fund. 2 The Advisor may use a variety of methods for security selection. As the Fund primarily focuses on certain industries, the Advisor intends to select companies with dominant positions in their respective markets, or those in unique positions for growth and expansion. The Advisor will utilize numerous outside analyst ratings and stock selection rating tools. In addition, the Advisor may invest the Fund's assets in lesser-known companies that the Advisor believes have a unique opportunity for growth. At times, the Advisor may aim to buy certain out-of-favor stocks believed to be at prices below their future potential value, as measured by the Advisor or outside analysts. The Fund may sell a security when the Advisor believes that the security is overvalued or better investment opportunities are available, or to limit position size within the Fund's portfolio.
Management and Contact
- Adviser
- AdvisorShares Investments, LLC
- Phone
- 877.843.3831
- [email protected]
- Website
- advisorshares.com/etfs/psil
Holdings as of Nov 17, 2026
The full portfolio the fund publishes every business day on its website (advisorshares.com). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 16, 2026.
29 lines, 22 linked, weights sum to 99.98% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| DEFINIUM THERAPEUTICS INC | DFTX 24477V105 | Equity | 153,124 | 0 | 11.81% | $ 4.499M |
| COMPASS PATHWAYS PLC | CMPS 20451W101 | Equity | 494,395 | 0 | 10.35% | $ 3.945M |
| HELUS PHARMA INC | HELP 423492107 | Equity | 392,147 | 0 | 7.41% | $ 2.823M |
| ELI LILLY & CO | LLY 532457108 | Equity | 1,860 | 0 | 6.91% | $ 2.633M |
| NEUROCRINE BIOSCIENCES INC | NBIX 64125C109 | Equity | 14,954 | 0 | 6.51% | $ 2.481M |
| ABBVIE INC | ABBV 00287Y109 | Equity | 8,071 | 0 | 6.20% | $ 2.363M |
| SUPERNUS INC | SUPN 45579U109 | Equity | 71,341 | 0 | 5.44% | $ 2.072M |
| RELMADA THERAPEUTICS INC | RLMD 75955J402 | Equity | 663,176 | 0 | 5.24% | $ 1.996M |
| SEAPORT THERAPEUTICS INC | SPTX 81221K108 | Equity | 109,334 | 0 | 5.21% | $ 1.987M |
| JOHNSON & JOHNSON | JNJ 478160104 | Equity | 6,842 | 0 | 5.00% | $ 1.907M |
| GH RESEARCH PLC | GHRS G3855L106 | Equity | 102,038 | 0 | 4.89% | $ 1.864M |
| NRX PHARMACEUTICALS INC | NRXP 629444209 | Equity | 740,811 | 0 | 4.76% | $ 1.815M |
| ALTO NEUROSCIENCE INC | ANRO 02157Q109 | Equity | 71,847 | 0 | 4.70% | $ 1.79M |
| NEURONETICS INC | STIM 64131A105 | Equity | 1,098,644 | 0 | 3.69% | $ 1.406M |
| BRIGHT MINDS BIOSCIENCES INC | DRUG 10919W405 | Equity | 48,217 | 0 | 2.60% | $ 988.931K |
| NEUPHORIA THERAPEUTICS INC | NEUP 64136E102 | Equity | 290,653 | 0 | 1.73% | $ 659.782K |
| PSYENCE BIOMEDICAL LTD | PBM 74449F407 | Equity | 258,157 | 0 | 1.70% | $ 647.974K |
| QUANTUM BIOPHARMA-B SUB VOT | QNTM 74764Y205 | Equity | 391,932 | 0 | 1.64% | $ 623.172K |
| OPTIMI HEALTH CORP | OPTH 68405H308 | Equity | 266,914 | 0 | 1.47% | $ 560.519K |
|
BLACKROCK TREASURY TRUST INSTL 62
|
X9USDBLYT | Money market | 344,797.13 | +216,150.39 | 0.90% | $ 344.797K |
| INCANNEX HEALTHCARE INC | IXHL 45333F208 | Equity | 156,359 | 0 | 0.71% | $ 272.065K |
|
NUMINUS WELLNESS INC
|
NUMIF 67054W103 | Equity | 9,748,746 | 0 | 0.44% | $ 166.704K |
| IGC PHARMA INC | IGC 45408X308 | Equity | 872,689 | 0 | 0.43% | $ 163.978K |
| SILO PHARMA INC | SILO 82711P300 | Equity | 96,113 | 0 | 0.42% | $ 161.47K |
|
CASH
|
Cash short | -66,929.47 | −217,026.61 | -0.18% | $ -66.929K | |
|
CONTRA ATAIBECKLEY INC
|
046CVR015 | Equity | 606,427 | 0 | — | — |
|
QUANTUM BIOPHARMA LTD
|
747CNT053 | Equity | 46,617 | 0 | — | — |
|
SAGE THERAPEUTICS CVR
|
786CVR019 | Equity | 89,780 | 0 | — | — |
|
UNBUZZD WELLNESS INC
|
BMY9R83 | Equity | 10,967 | 0 | — | — |
Trades Nov 16, 2026 to Nov 17, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up